Literature DB >> 14997032

P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia.

Bernt van den Blink1, Judith Branger, Sebastiaan Weijer, Abhya Gupta, Sander J H van Deventer, Maikel P Peppelenbosch, Tom van der Poll.   

Abstract

Chemokine receptors CXC receptor (CXCR) 1 and 2, and their ligands interleukin (IL)-8 and growth-related oncogene alpha (GRO alpha), are principal regulators of neutrophil activation and migration. To investigate the role of p38 mitogen activated protein kinase (MAPK) in the regulation of CXCR expression during an inflammatory response in vivo, 24 healthy volunteers received an intravenous injection with lipopolysaccharide (LPS) preceded (-3 hr) by a specific p38 MAPK inhibitor (BIRB 796 BS) at a high dose (600 mg) or a low dose (50 mg) or a placebo. The LPS-induced reduction of neutrophil CXCR 1 and 2 expression, as determined by fluorescence-activated cell sorter analysis, was inhibited in volunteers receiving the high dose of the p38 MAPK inhibitor. The kinase inhibitor also dose dependently diminished the LPS-induced rises in plasma IL-8 and GRO alpha levels. These results indicate a principal role for p38 MAPK in regulating factors essential for neutrophil activation and chemotaxis in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997032     DOI: 10.1023/B:JOCI.0000018061.58504.75

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  17 in total

Review 1.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.

Authors:  J M Kyriakis; J Avruch
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis.

Authors:  C J Cummings; T R Martin; C W Frevert; J M Quan; V A Wong; S M Mongovin; T R Hagen; K P Steinberg; R B Goodman
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

3.  Chemoattractant cross-desensitization of the human neutrophil IL-8 receptor involves receptor internalization and differential receptor subtype regulation.

Authors:  I Sabroe; T J Williams; C A Hébert; P D Collins
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

4.  Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans.

Authors:  T van der Poll; S M Coyle; M Levi; P M Jansen; M Dentener; K Barbosa; W A Buurman; C E Hack; J W ten Cate; J M Agosti; S F Lowry
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

5.  Expression of the chemokine receptors CXCR1 and CXCR2 on granulocytes in human endotoxemia and tuberculosis: involvement of the p38 mitogen-activated protein kinase pathway.

Authors:  N P Juffermans; P E Dekkers; M P Peppelenbosch; P Speelman; S J van Deventer; T van Der Poll
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

6.  Reduced expression of interleukin-8 receptors A and B on polymorphonuclear neutrophils from persons with human immunodeficiency virus type 1 disease and pulmonary tuberculosis.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

7.  Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide.

Authors:  J A Nick; N J Avdi; P Gerwins; G L Johnson; G S Worthen
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

8.  Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins.

Authors:  C Marie; S Roman-Roman; G Rawadi
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

9.  Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.

Authors:  Judith Branger; Bernt van den Blink; Sebastiaan Weijer; Jeffrey Madwed; Carina L Bos; Abhya Gupta; Chan-Loi Yong; Stephen H Polmar; Dariusz P Olszyna; C Erik Hack; Sander J H van Deventer; Maikel P Peppelenbosch; Tom van der Poll
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  5 in total

1.  LOX-1 deletion improves neutrophil responses, enhances bacterial clearance, and reduces lung injury in a murine polymicrobial sepsis model.

Authors:  Zhuang Wu; Tatsuya Sawamura; Anna K Kurdowska; Hong-Long Ji; Steven Idell; Jian Fu
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

2.  CNS leptin action modulates immune response and survival in sepsis.

Authors:  Johannes Tschöp; Ruben Nogueiras; Sarah Haas-Lockie; Kevin R Kasten; Tamara R Castañeda; Nadine Huber; Kelsey Guanciale; Diego Perez-Tilve; Kirk Habegger; Nickki Ottaway; Stephen C Woods; Brian Oldfield; Iain Clarke; Streamson Chua; I Sadaf Farooqi; Stephen O'Rahilly; Charles C Caldwell; Matthias H Tschöp
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

3.  BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types.

Authors:  Soyoon Ryoo; Jida Choi; Jaemyung Kim; Suyoung Bae; Jaewoo Hong; Seunghyun Jo; Soohyun Kim; Youngmin Lee
Journal:  Immune Netw       Date:  2013-12-20       Impact factor: 6.303

Review 4.  Science review: mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids.

Authors:  Hélène Prigent; Virginie Maxime; Djillali Annane
Journal:  Crit Care       Date:  2004-05-25       Impact factor: 9.097

5.  Activation of p38MAPK contributes to expanded polyglutamine-induced cytotoxicity.

Authors:  Maria Tsirigotis; R Mitchell Baldwin; Matthew Y Tang; Ian A J Lorimer; Douglas A Gray
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.